Heartbeat.bio
Address: Vienna Biocenter 6, Dr. Bohr-Gasse 7, Vienna, A-1030About Us
HeartBeat.bio is a pioneering TechBio company leveraging a next-generation drug discovery platform to develop breakthrough medicines for heart failure patients. Heart failure is a rapidly growing global health crisis, affecting over 30 million people in major pharmaceutical markets, with limited treatment options. Despite its prevalence, innovation in this space has lagged—creating a massive opportunity for disruption. Our proprietary Cardioid Drug Discovery Platform integrates iPSC-derived cardiac organoids with AI-driven analytics and advanced automation. Unlike traditional drug discovery, which relies heavily on animal models with poor clinical translatability, our human-centric approach enables more predictive, efficient, and cost-effective drug development. By combining physiologically relevant human models with cutting-edge technology, we aim to accelerate drug discovery, reduce failure rates, and bring novel therapies to patients faster. We are advancing our own pipeline while strategically partnering with pharma and biotech companies to co-develop transformative heart failure treatments. Recently, we closed our first longer-term partnership deal with a leading player in cardiovascular disease. Initial focus areas include cardiomyopathies, myocardial fibrosis, and cardiac remodeling—high-impact indications with significant unmet needs.
Sectors
- Collaborations & Partnerships- R&D
- Collaborations & Partnerships-Services
- Collaborations & Partnerships-Manufacture
- Proprietary Research & Manufacture
Categories
- Biologics
- Drug Discovery Services
- Platform Technology-Drug Discovery
- Cardiovascular Products
- Compound Screening
- Organoids
- Disease Model Services
- Bioassay Development
- Analytical Method Development & Validation
- Automation Technology
- Bioanalysis
News
HeartBeat.bio Joins Forces with Boehringer Ingelheim to Advance Gene Therapies for Inherited Heart Muscle Disorders
Vienna, Austria – September 23, 2025 – HeartBeat.bio has entered into a research collaboration with Boehringer Ingelheim to develop gene therapy-based treatments for genetic cardiomyopathies. The partnership combines Boehringer Ingelheim’s expertise in gene therapy drug development with HeartBeat.bio’s proprietary Cardioid Drug Discovery Platform, aiming to advance innovative therapies for inherited heart muscle diseases.
The partnership addresses a high unmet need in cardiovascular health. Genetic cardiomyopathies - including hypertrophic, dilated, and arrhythmogenic forms - are a leading cause of heart failure and sudden cardiac death, particularly among younger individuals. Across major pharmaceutical markets (US, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan), approximately one million people are affected, many of whom face limited treatment options and a high burden of disease.
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com